Cargando…
Androgen deprivation therapy in castrate-resistant prostate cancer: how important is GnRH agonist backbone therapy?
BACKGROUND: A growing number of treatment options exist to treat metastatic castrate-resistant prostate cancer (mCRPC), and with these newer options, many questions about optimising treatment remain unanswered. One recommendation that may potentially be overlooked by practitioners is that androgen d...
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Berlin Heidelberg
2014
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4512260/ https://www.ncbi.nlm.nih.gov/pubmed/25261259 http://dx.doi.org/10.1007/s00345-014-1406-2 |